Ubs Asset Management Americas Inc Gritstone Bio, Inc. Transaction History

Ubs Asset Management Americas Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$2.63 - $8.09 $921,722 - $2.84 Million	-350,465 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$5.69 - $8.17 $80,012 - $114,886	14,062 Added 4.18%	350,465 $2.33 Million
Q1 2020 May 15, 2020	SELL	$5.47 - $11.3 $280,818 - $580,119	-51,338 Reduced 13.24%	336,403 $1.96 Million
Q4 2019 Feb 14, 2020	SELL	$7.07 - $11.61 $19,923 - $32,716	-2,818 Reduced 0.72%	387,741 $3.48 Million
Q3 2019 Nov 14, 2019	SELL	$8.45 - $12.28 $107,298 - $155,931	-12,698 Reduced 3.15%	390,559 $3.37 Million
Q2 2019 Aug 15, 2019	BUY	$9.2 - $15.7 $1.18 Million - $2.01 Million	128,062 Added 46.54%	403,257 $0
Q1 2019 May 14, 2019	BUY	$9.97 - $18.96 $594,401 - $1.13 Million	59,619 Added 27.66%	275,195 $0
Q4 2018 Feb 13, 2019	BUY	$11.61 - $31.1 $2.5 Million - $6.7 Million	215,576 New	215,576 $3.33 Million

1.2M

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.